Oshima et al revealed that KRAS-G12D mouse T-ALL tumors were specifically resistant to methotrexate instead of steroids and displayed increased sensitivity to vincristine treatment.35 Together, these findings suggest that better characterization of GR synergy with other TFs is necessary for the design of better treatments. The gene discussed is KRAS; the disease is acute lymphoblastic leukemia.